Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Piperazinedione given iv once every 3-4 weeks at a starting dose of 9-12 mg/m2 (4.5-12 mg/m2 for patients with myeloma) was evaluated in a Southwest Oncology Group phase II study for patients with far-advanced refractory lymphoma or multiple myeloma. Among 36 patients fully evaluable for tumor response (adequate trial), partial responses were observed in five (71%) of seven patients with Hodgkin's disease, in three (19%) of 16 patients with non-Hodgkin's lymphoma, and in none of 13 patients with multiple myeloma. Response was observed by the time of the second (five patients) or third (three patients) course. The median duration of response was 3.7 months (range, 1-17+ months). The dose-limiting toxic effects were hematologic, with 18 (50%) of 36 patients evaluable for toxicity experiencing severe leukopenia (wbc count less than 2000/mm3) and 22 (61%) experiencing severe thrombocytopenia (platelet count less than 50,000/mm3). Twenty patients had a decrease from their pretreatment hemoglobin level of greater than or equal to 2 g/100 ml. Hematologic toxic effects were often unpredictable and in several patients quite prolonged. This study indicates that piperazinedione had definite antitumor activity in patients with Hodgkin's disease and further trials in this disease using the drug at a reduced dose in combination with other effective drugs appear warranted.
Cancer Treat Rep 1977 Dec
PMID:Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study. 34 32

Prophylactic irradiation of the skull and intrathecal application of methotrexate has proven to be highly effective in preventing central nervous system disease in acute lymphoblastic leukemia or non-Hodgkin-lymphoma. Prophylactic treatment may be complicated by a somnolence syndrome occuring 4--8 weaks after the end of irradiation. The main features of this clinical entity are somnolence, lethargy, dullness, anorexia, headache, and vomiting. EEG frequently displays a distinct slowing of activity. All symptoms are reversible after 3--49 days. The syndrome clearly is consequence of skull irradiation. Its metabolic basis probably is transient disturbance of myelinization.
Monatsschr Kinderheilkd 1978 Dec
PMID:[Non-leukemic disease of the central nervous system in children with acute lymphoblastic leukemia. I. Somnolence syndrome (author's transl)]. 36 88

Fifteen primary intracranial reticulum cell sarcomas and five cases with an additional solitary extracranial tumor mass have been studied. For comparison, seven extracranial malignant non-Hodgkin lymphomas and normal lymphoid tissue were included. The methods used on formalin-fixed paraffin-embedded tissue sections were an immunoperoxidase technique for the demonstration of intracellular immunoglobulins, microglial staining, Gomori's reticulin, methylgreen-pyronin, Giemsa, diastase resistant PAS, Mallory's PTAH and H&E. Electron microscopy was performed in one primary brain tumor. According to histopathologic criteria all tumors could be classified as malignant non-Hodgkin lymphomas, predominantly of the pleomorphic immunocytic or of the immunoblastic type; follicular lymphomas were notably absent. In all cases intracellular immunoglobulins were demonstrable in tumor cells and in a majority of the tumors these were monoclonal. Thus, all malignant lymphomas proved to be of B cell origin with demonstrable cytoplasmic immunoglobulin production. Based on the microglial staining more than half of the malignant lymphomas could also be classified as microgliomas. As a comparable staining was present in non-Hodgkin lymphomas outside the CNS, microglioma characteristics are not associated with intracranial growth.
Acta Neuropathol 1978 Dec 15
PMID:Intracranial malignant lymphomas. A morphologic and immunocytologic study of twenty cases. 36 44

This paper reviews the changes of blood and peripheral lymph lymphocytes induced by therapeutic irradiation as given for a variety of lymphoid and nonlymphoid neoplastic diseases. The irradiation brings about an abrupt reduction of the numbers of blood B and T lymphocytes. The number of lymphocytes seems to be restored within a few months after irradiation, while at least 3-5 years appear to pass before the number of blood T lymphocytes is restored. The pattern of recovery seems to be the same whether the thymus has been included in the fields of irradiation or not. In the adult organism, considerable differences apparently exist between the capacities for reproduction of B and T lymphocytes. The number of lymphocytes in peripheral lymph is also much reduced in the irradiated patient and remains so for a long period. This is compatible with the concept that migration from blood to peripheral lymph is a feature quite specific for T lymphocytes. These results are discussed in relation to the immune defense against infection and autologous tumor, and also in relation to the influence of radiotherapy on the immune defect in Hodgkin's disease.
Lymphology 1978 Dec
PMID:The influence of therapeutic irradiation of blood and peripheral lymph lymphocytes. 36 38

DTIC, a new cytostatic drug developed by the NCI-USA, is described and some relevant pharmacological characteristics are defined. This drug was proved to be the number one choice for the treatment of malignant melanoma and of sarcomas. It also appears to be of value in advanced cases of Hodgkins disease. DTIC represents a very valuable addition to the available drugs for chemotherapy of malignant tumours.
Wien Klin Wochenschr 1978 Dec 22
PMID:[Pharmacology of DTIC (author's transl)]. 36 50

Indications and results are reviewed with regard to recent data on the effect of DTIC in patients with malignant melanoma, soft tissue sarcomas, Hodgkin's disease, gastrointestinal carcinomas and oat cell cancer of the lung. Whilst this drug induced--mainly partial--remissions in 25% of the patients with melanomas, it is generally used in other malignant conditions in combination with other cytoxic agents. In soft tissue sarcomas adriamycin appeared as the principal additional drug. In patients with Hodgkin's disease resistant to MOPP treatment and requiring additional cytotoxic drugs, combination chemotherapy including DTIC may induce remissions in more than half of these patients. Other schedules were, however, also effective and results in this difficult group of patients are discussed and compared. In gastrointestinal and in oat cell carcinomas cytotoxic protocols including DTIC have shown some effect, perhaps comparable to other combinations usually employed in these conditions.
Wien Klin Wochenschr 1978 Dec 22
PMID:[Dacarbacine (DTIC) in the therapy of a malignant disease. A review (author's transl)]. 36 51

22 patients with malignant non-Hodgkin lymphoma resistant to conventional chemotherapy were treated with high-dose combination chemotherapy followed in the first 12 patients by infusion of their cryopreserved autologous bone marrow. The next 10 patients received chemotherapy alone. Four patients died shortly after chemotherapy. Four patients remain in unmaintained remission 40, 30, 20 and 8 months after treatment. Patients receiving cryopreserved marrow recovered leukocyte, granulocyte and platelet function significantly faster and had significantly fewer febrile days than did controls. These findings demonstrate that high dose combination chemotherapy may benefit some patients unresponsive to conventional chemotherapy, and that cryopreserved bone marrow can speed hematopoetic recovery and be of clinical benefit to the patient.
Schweiz Med Wochenschr 1978 Dec 09
PMID:[Long-term, complete remission in non-Hodgkin's lymphoma following high-dosage combination therapy with or without autologous bone marrow transplantation]. 37 98

This study reports 35 cases of posttherapeutic acute leukemia and reviews the literature on this subject. These AL's are characterized by a high incidence of anemia, in particular refractory anemia, preceding the hematological disorder by several months, by the frequent finding of myelofibrosis, by the essentially granulocytic nature of the AL, and by the low rate of remission and the, in general, extremely short sruvival of a few months. These leukemias may develop following continuous chemotherapy with an alkylating agent, radiotherapy of various extent, or most commonly following intensive treatment with extensive irradiation and polychemotherapy as in the management of Hodgkin's disease. In view of these therapeutic hazards, the present objectives are the modification of alkylating agent therapy by the use of other drugs and sequential administration, and a reduction in the dose and field of irradiation and the duration of polychemotherapy, as in Hodgkin's disease; all present protocols are orientated in this direction.
Cancer 1979 Dec
PMID:Post-therapeutic acute leukemia. 38 5

75 cases of primary lymphomas of bone ("reticulum cell sarcoma" described by Parker and Jackson) were reviewed. Biopsy specimens were classified according to several histological classifications, including Lukes' classification for nodal lymphomas. Among 24 tumors described as "histiocytic lymphomas" in Rappaport's classification of 1966, only one case remains as "true histiocytic sarcoma". The others were reclassified as follows : 6 tumors with a predominance of large cleaved cells, 13 tumors with large non-cleaved cells, 2 as immunoblastic tumors and 2 as unclassifiable. In non Hodgkin's lymphomas, the histological diagnosis and the results of the initial staging have been shown to be greater aids in the prediction of survival than the primary site of the disease. Therefore, the clinical and therapeutical approach to the patients with lymphomas of bone must be modified to be similar to that of patients with nodal localisations of the disease.
Biomedicine 1979 Dec
PMID:Primary lymphomas of bone (so-called ("Parker and Jackson's reticulum cell sarcoma") : histological review of 75 cases according to the new classifications of non Hodgkin's lymphomas. 39 45

Thirty-nine patients with clinically staged IA and IIA Hodgkin's disease were treated with mantle plus paraaortic/splenic irradiation between 1968 and 1975. All patients had supradiaphragmatic presentations, and none had staging laparotomies. With a follow-up time of 1 to 9 years, mean 4.3 years, the overall relapse-free survival is 92% (100% for stage IA and 89% for stage IIA). The absolute relapse-free 5-year survival is 91% There were no pelvic recurrences. These data show that routine staging laparotomy and pelvic irradiation are not indicated for clinically staged IA and IIA Hodgkin's disease with supradiaphragmatic presentation. The criteria for staging laparotomy in early-stage Hodgkin's disease are discussed.
Cancer 1977 Dec
PMID:Are pelvic irradiation and routine staging laparotomy necessary in clinically staged IA and IIA Hodgkin's disease? 41 83


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>